EODData

MEMBERSHIP REGISTER LOG IN

FRA, 19X: Axsome Therapeutics Inc

06 Nov 2025
LAST:

116.5

CHANGE:
 0.25		OPEN:
116.5		HIGH:
116.5		ASK:
0.0		VOLUME:
20
CHG(%):
0.22		PREV:
116.2		LOW:
116.5		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 25116.5116.5116.5116.520
05 Nov 25116.3116.3116.2116.220
04 Nov 25115.6115.6115.6115.625
31 Oct 25116.3116.3116.3116.340
30 Oct 25113.5115.8113.5115.829
29 Oct 25113.9113.9113.9113.955
28 Oct 25114.3116.6114.3116.555
27 Oct 25110.8114.9110.6114.244
24 Oct 25108.4110.2108.4110.230
23 Oct 25110.5110.5110.5110.5335

COMPANY PROFILE

Name:Axsome Therapeutics Inc
About:Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:One World Trade Center, New York, NY, United States, 10007
Website:https://www.axsome.com
ISIN:US05464T1043
LEI:549300EXGR0XLRJEIB95

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-19.30 
Forward P/E:-30.18 
PEG Ratio:0.46 
Price to Sales:11.65 
Price to Book:78.80 
Profit Margin:-0.50 
Operating Margin:-0.30 
Return on Assets:-0.22 
Return on Equity:-2.81 
Revenue:428.85M 
Shares:49.9M 
Market Cap:5.811B 

TECHNICAL INDICATORS

MA5:116.060.3%
MA10:114.551.7%
MA20:111.114.8%
MA50:105.7310.1%
MA100:98.2018.6%
MA200:100.7815.6%
STO9:98.44 
STO14:99.15 
RSI14:60.86 
WPR14:-0.43 
MTM14:11.60
ROC14:0.11 
ATR:2.38 
Week High:116.450.0%
Week Low:113.452.6%
Month High:116.550.1%
Month Low:100.8515.6%
Year High:134.9115.9%
Year Low:69.4167.8%
Volatility:26.99